Cited 0 times in Scipus Cited Count

High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy

DC Field Value Language
dc.contributor.authorChoi, YW-
dc.contributor.authorAhn, MS-
dc.contributor.authorChoi, JH-
dc.contributor.authorLee, HW-
dc.contributor.authorKang, SY-
dc.contributor.authorJeong, SH-
dc.contributor.authorPark, JS-
dc.contributor.authorHan, JH-
dc.contributor.authorKim, JH-
dc.contributor.authorSheen, SS-
dc.date.accessioned2018-05-04T00:25:02Z-
dc.date.available2018-05-04T00:25:02Z-
dc.date.issued2016-
dc.identifier.issn0925-5710-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14949-
dc.description.abstractThe prognostic significance of Bcl-2, Bcl-6, p53, topoisomerase II, and beta-tubulin expression was evaluated in diffuse large B-cell lymphoma (DLBCL) patients treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab. Eight-year progression-free survival (PFS, P = 0.006) and overall survival (OS, P = 0.001) of patients with high Bcl-2 expression were significantly inferior to those of patients with low expression without prognostic significance of Bcl-6, p53, topoisomerase II, and beta-tubulin expression. High expression of Bcl-2 was associated with poor PFS (P = 0.045) and OS (P = 0.004) only in patients with low international prognostic index (IPI). In multivariate analysis, high expression of Bcl-2 was a significant independent prognostic factor of poor PFS (P = 0.026) and OS (P = 0.007) along with high IPI. In conclusion, the expression of Bcl-2 may be a useful prognostic factor, especially in DLBCL patients with low IPI.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntibodies, Monoclonal, Murine-Derived-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHCyclophosphamide-
dc.subject.MESHDoxorubicin-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression-
dc.subject.MESHGene Expression Regulation, Neoplastic-
dc.subject.MESHHumans-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHPrednisone-
dc.subject.MESHProto-Oncogene Proteins c-bcl-2-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHVincristine-
dc.titleHigh expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy-
dc.typeArticle-
dc.identifier.pmid26586460-
dc.contributor.affiliatedAuthor최, 용원-
dc.contributor.affiliatedAuthor안, 미선-
dc.contributor.affiliatedAuthor최, 진혁-
dc.contributor.affiliatedAuthor이, 현우-
dc.contributor.affiliatedAuthor강, 석윤-
dc.contributor.affiliatedAuthor정, 성현-
dc.contributor.affiliatedAuthor박, 준성-
dc.contributor.affiliatedAuthor한, 재호-
dc.contributor.affiliatedAuthor김, 장희-
dc.contributor.affiliatedAuthor신, 승수-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s12185-015-1911-0-
dc.citation.titleInternational journal of hematology-
dc.citation.volume103-
dc.citation.number2-
dc.citation.date2016-
dc.citation.startPage210-
dc.citation.endPage218-
dc.identifier.bibliographicCitationInternational journal of hematology, 103(2). : 210-218, 2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1865-3774-
dc.relation.journalidJ009255710-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse